Abdelrahman Gad

Abdelrahman Gad

Auto-generated profile, based on publicly available information

Abdelrahman Gad

The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 December 2021 in PLOS ONE
Verified
Journal Article
Open access
PDF file
Nguyen Tien HuyNguyen Tien Huy
Nguyen Tien Huy
RCR. Matthew Chico
R. Matthew Chico
VHVuong Thanh Huan
Vuong Thanh Huan
HSHosam Waleed Shaikhkhalil
Hosam Waleed Shaikhkhalil
VUVuong Ngoc Thao Uyen
Vuong Ngoc Thao Uyen
ISIbrahim Shammas
Ibrahim Shammas
Background: Since the COVID-19 pandemic began, there have been concerns related to the preparedness of healthcare workers (HCWs). This study aimed to describe the level of awareness and preparedness of hospital HCWs at the time of the first wave. Methods: This multinational, multicenter, cross-sectional survey was conducted among hospital HCWs from February to May 2020. We used a hierarchical logistic regression multivariate analysis to adjust the influence of variables based on awareness and preparedness. We then used association rule mining to identify relationships between HCW confidence in handling suspected COVID-19 patients and prior COVID-19 case-management training. Results: We surveyed 24,653 HCWs from 371 hospitals across 57 countries and received 17,302 responses from 70.2% HCWs overall. The median COVID-19 preparedness score was 11.0 (interquartile range [IQR] = 6.0–14.0) and the median awareness score was 29.6 (IQR = 26.6–32.6). HCWs at COVID-19 designated facilities with previous outbreak experience, or HCWs who were trained for dealing with the SARS-CoV-2 outbreak, had significantly higher levels of preparedness and awareness (p<0.001). Association rule mining suggests that nurses and doctors who had a ’great-extent-of-confidence’ in handling suspected COVID-19 patients had participated in COVID-19 training courses. Male participants (mean difference = 0.34; 95% CI = 0.22, 0.46; p<0.001) and nurses (mean difference = 0.67; 95% CI = 0.53, 0.81; p<0.001) had higher preparedness scores compared to women participants and doctors. Interpretation: There was an unsurprising high level of awareness and preparedness among HCWs who participated in COVID-19 training courses. However, disparity existed along the lines of gender and type of HCW. It is unknown whether the difference in COVID-19 preparedness that we detected early in the pandemic may have translated into disproportionate SARS-CoV-2 burden of disease by gender or HCW type.

2 September 2021 in Reviews in Medical Virology
Verified
Journal Article
Open access
PDF file
Minh H. N. LeMinh H. N. Le
Minh H. N. Le
AAAli Ahmed‐Fouad Abozaid
Ali Ahmed‐Fouad Abozaid
NHNam Xuan Ha
Nam Xuan Ha
LQLoc Le Quang
Loc Le Quang
AGAbdelrahman Gamil Gad
Abdelrahman Gamil Gad
Nguyen Tien HuyNguyen Tien Huy
Nguyen Tien Huy
Summary: SARS Coronavirus‐2 is one of the most widespread viruses globally during the 21st century, whose severity and ability to cause severe pneumonia and death vary. We performed a comprehensive systematic review of all studies that met our standardised criteria and then extracted data on the age, symptoms, and different treatments of Covid‐19 patients and the prognosis of this disease during follow‐up. Cases in this study were divided according to severity and death status and meta‐analysed separately using raw mean and single proportion methods. We included 171 complete studies including 62,909 confirmed cases of Covid‐19, of which 148 studies were meta‐analysed. Symptoms clearly emerged in an escalating manner from mild‐moderate symptoms, pneumonia, severe‐critical to the group of non‐survivors. Hypertension (Pooled proportion (PP): 0.48 [95% Confident interval (CI): 0.35–0.61]), diabetes (PP: 0.23 [95% CI: 0.16–0.33]) and smoking (PP: 0.12 [95% CI: 0.03–0.38]) were highest regarding pre‐infection comorbidities in the non‐survivor group. While acute respiratory distress syndrome (PP: 0.49 [95% CI: 0.29–0.78]), (PP: 0.63 [95% CI: 0.34–0.97]) remained one of the most common complications in the severe and death group respectively. Bilateral ground‐glass opacification (PP: 0.68 [95% CI: 0.59–0.75]) was the most visible radiological image. The mortality rates estimated (PP: 0.11 [95% CI: 0.06–0.19]), (PP: 0.03 [95% CI: 0.01–0.05]), and (PP: 0.01 [95% CI: 0–0.3]) in severe‐critical, pneumonia and mild‐moderate groups respectively. This study can serve as a high evidence guideline for different clinical presentations of Covid‐19, graded from mild to severe, and for special forms like pneumonia and death groups.

7 March 2020 in SSRN Electronic Journal
Verified
Preprint
Open access
PDF file
AQAhmad Taysir Atieh Qarawi
Ahmad Taysir Atieh Qarawi
SNSze Jia Ng
Sze Jia Ng
AGAbdelrahman Gad
Abdelrahman Gad
LMLuu Ngoc Mai
Luu Ngoc Mai
TATareq Mohammed Ali Al-Ahdal
Tareq Mohammed Ali Al-Ahdal
Nguyen Tien HuyNguyen Tien Huy
Nguyen Tien Huy
The recent outbreak of respiratory illness caused by a novel coronavirus (named “COVID-2019”) has gained attention globally and has been recognized as a serious public health threat by US Centers for Disease Control and Prevention (CDC). The first case was detected in Wuhan City, Hubei Province, China and since then, the disease has spread rapidly. As of February 28, 2020, the World Health Organization (WHO) declared that the outbreak of COVID-2019 as a Public Health Emergency of International Concern (PHEIC) with 62 countries now reporting 85,176 confirmed cases (79,250 of which have been in mainland China) and 2,919 deaths to date. However, information about the health systems and health professionals’ preparedness for combating the 2019-nCoV is not known. Therefore, their awareness and preparedness in managing the 2019-nCoV infection are important to prevent the further spread of the disease. This is a multicenter multinational survey aiming to assess the level of preparedness of hospital staff and practices regarding COVID-2019 all over the world and their preparedness to deal with the outbreak. It will also measure the level of awareness of hospital staff about the crisis and how will they react to limit and prevent further transmission.

13 December 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
NTNguyen Thanh Tam
Nguyen Thanh Tam
ASAhmed M. Sayed
Ahmed M. Sayed
MDMohammad Najm Dadam
Mohammad Najm Dadam
RERanda Elsheikh
Randa Elsheikh
Jeza Muhamad Abdul AzizJeza Muhamad Abdul Aziz
Jeza Muhamad Abdul Aziz
Nguyen Tien HuyNguyen Tien Huy
Nguyen Tien Huy
Despite infectious diseases being a significant threat to global health, there are continuing concerns that regulatory authorities do not prioritize therapeutic strategies for infectious diseases with the same urgency as those for oncological or orphan diseases. This study aims to examine the differences in the productivity of drug development and approval procedures between non-infectious and infectious diseases, and to determine the utilization patterns of acceleration programs. All molecules and biologic products approved between January 1, 2015, and December 31, 2024 (N = 464) were subject to a cross-sectional study. Drugs@FDA, the Federal Register, and ClinicalTrials.gov were used as sources of data to establish median Clinical Development Time (CDT), Regulatory Approval Time (RAT), and cumulative Regulatory Review Time (RRT). Kruskal–Wallis tests were used to compare median values (interquartile range, IQR), and chi-square tests were used for proportions. Time-to-event differences were tested using Kaplan–Meier analyses with log-rank testing, and hazard ratios (HRs) were calculated using Cox proportional hazards models. Multivariable logistic regression with interaction terms was used to model Priority Review, Fast Track, Breakthrough Therapy, and Accelerated Approval, reporting adjusted odds ratios (aOR). Of 464 approvals, 65 (14.0%) targeted infectious diseases. Median CDT was 2.76 years (IQR 1.80–4.25) versus 3.46 years (IQR 2.59–4.66; p = 0.003), and median RRT was 3.54 years (IQR 2.58–5.03) versus 4.22 years (IQR 3.24–5.73; p = 0.006) for infectious and non‑infectious drugs, respectively. Nevertheless, infectious agents were approved 58% faster (HR = 1.58; 95% CI 1.15–2.16; p = 0.0047). Infectious disease products were more likely to receive Fast Track (OR = 4.49; 95% CI 2.39–8.70) and Priority Review (OR = 10.69; 95% CI 4.57–29.50) but less likely to obtain Breakthrough Therapy (OR = 0.42; 95% CI 0.28–0.63) or Accelerated Approval (OR = 0.12; 95% CI 0.016–0.56). Infectious disease treatments outpace non-infectious disease treatments in terms of drug development and approval timelines. Nevertheless, they are less frequently utilized in pathways like Accelerated Approval, which are scientifically less applicable to acute-disease endpoints. Therefore, policy reforms should focus on addressing the underlying economic and scientific barriers to anti-infective innovation.

11 March 2026 in Reviews in Medical Virology
Verified
Journal Article
Closed access
HCHuynh Tran Bao Chau
Huynh Tran Bao Chau
BMBui Cong Minh
Bui Cong Minh
Jeza Muhamad Abdul AzizJeza Muhamad Abdul Aziz
Jeza Muhamad Abdul Aziz
HVHoang Bao Tran Van
Hoang Bao Tran Van
BTBui Nguyen Ha Tien
Bui Nguyen Ha Tien
Nguyen Tien HuyNguyen Tien Huy
Nguyen Tien Huy

4 October 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
SMSaipavitra Murali-Manohar
Saipavitra Murali-Manohar
AGAbdelrahman Gad
Abdelrahman Gad
ZSZahra Shams
Zahra Shams
GSGizeaddis L. Simegn
Gizeaddis L. Simegn
YSyulu song
yulu song
RERichard A.E. Edden
Richard A.E. Edden
Purpose: With growing interest in pediatric MRS to understand the neurochemistry of brain development, it is essential to establish pediatric-specific metabolite T 1 and T 2 relaxation times for reliable quantification of metabolites. Furthermore, characterization of age-related changes in relaxation times may provide insight into developmental differences in tissue microstructure and cellular composition. Therefore, the goals of this study were two-fold: (1) to estimate metabolite T 1 and T 2 relaxation times in a pediatric cohort; and (2) to assess linear relationships between age and relaxation times. Methods: TI- and TE-series data were acquired from the bilateral thalamus in 20 and 25 participants aged between 0 and 7 years, respectively. Data were processed and modelled in Osprey 2.5.0. Metabolite T 1 and T 2 relaxation times of total N-acetylaspartate at 2.0 ppm (tNAA 2.0 ), total creatine at 3.0 ppm (tCr 3.0 ), total creatine at 3.9 ppm (tCr 3.9 ), total choline (tCho), myo-inositol (mI) and the combined glutamate and glutamine (Glx) were estimated by fitting the modelled signal amplitudes to TI-series inversion recovery signal and TE-series exponential decay equations, respectively. Linear relationships with age were tested for metabolite T 1 and T 2 relaxation times using Spearman correlations. Results: tNAA 2.0 and Glx showed significant changes in T 1 with age. tNAA 2.0 , tCr 3.0 , tCho and mI showed significant decrease in T 2 with age. Conclusion: Several metabolites showed significant changes in relaxation times with age in the thalamus region. Therefore, use of age-specific relaxation correction for pediatric studies using the linear equations provided is encouraged for reliable quantification of metabolites.